Nasdaq:CRIS
CURIS INC
A Nasdaq-listed biotech firm advancing a clinical-stage oncology portfolio with minimal current revenue but substantial cash burn.
Key Metrics
Investment Thesis
Bull Case
Investors may view this stock as a high-risk, high-reward speculative play on potential blockbuster oncology drugs nearing commercialization or successful licensing deals. The narrowing operating losses suggest improved operational efficiency and better cost management in R&D activities.
Bear Case
The company faces an existential threat due to its negative shareholders' equity of -$6M and a massive cash burn rate that depletes the $20M cash reserves rapidly. Without significant external funding or a major licensing deal, the firm risks insolvency given its current liabilities of $47.3M.
About CURIS INC
CRIS (CURIS INC) operates as a biotechnology company focused on developing novel therapeutic agents, primarily targeting oncology markets. The company generates revenue through product sales and licensing agreements while managing significant R&D expenditures to advance its pipeline. Key products include proprietary compounds designed to address unmet medical needs in cancer treatment.
Analysis
Management Discussion
Despite a narrowing net loss trend moving from -$56.7M in 2022 to -$43.4M in 2024, the company remains cash-flow negative with operating profits of -$44.5M. Management has successfully reduced losses while maintaining revenue growth to $10.9M, but the current liabilities exceed assets by $6M, indicating financial distress.
Industry Overview
The biotechnology industry is characterized by high capital intensity, long development cycles, and binary outcomes from clinical trials that can make or break a company. Competition is fierce among firms developing immunotherapies and targeted therapies for cancer patients seeking improved survival rates.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $10.2M | $10.0M | $10.9M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $10.2M | $10.0M | $10.9M |
| Operating Expenses | $63.2M | $58.4M | $55.5M |
| Operating Income | $-53.0M | $-48.3M | $-44.5M |
| G&A | $19.6M | $18.6M | $16.8M |
| Stock-Based Comp | $6.8M | $6.0M | $5.9M |
| D&A | $233.0K | $255.0K | $203.0K |
| Other OpEx | $43.5M | $39.7M | $38.7M |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | $1.1M | $2.9M | $1.8M |
| Pre-Tax Income | $-53.0M | $-48.3M | $-44.5M |
| Income Tax | $3.7M | $-919.0K | $-1.2M |
| Continuing Ops | $-56.7M | $-47.4M | $-43.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-56.7M | $-47.4M | $-43.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-56.7M | $-47.4M | $-43.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $92.1M | $60.9M | $26.4M |
| Cash & Equivalents | $19.7M | $26.7M | $20.0M |
| Marketable Securities | $66.0M | $29.7M | $0 |
| Accounts Receivable | $3.0M | $2.8M | $3.3M |
| Prepaid Expenses | $3.5M | $1.8M | $3.0M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $16.7M | $16.4M | $14.9M |
| PP&E (Net) | $689.0K | $434.0K | $231.0K |
| Goodwill | $9.0M | $9.0M | $9.0M |
| Operating Leases | $4.4M | $3.1M | $3.2M |
| LT Investments | $0 | — | — |
| Other LT Assets | $2.7M | $3.9M | $2.5M |
| Total Assets | $108.8M | $77.3M | $41.3M |
| Current Liabilities | $10.0M | $13.5M | $19.0M |
| Accounts Payable | $3.2M | $3.2M | $3.0M |
| Current Debt | — | — | $7.6M |
| Current Leases | $1.1M | $1.3M | $1.3M |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $52.3M | $44.1M | $28.2M |
| LT Operating Leases | $2.8M | $1.5M | $1.6M |
| Other LT Liab | $49.5M | $42.6M | $26.6M |
| Total Liabilities | $62.3M | $57.6M | $47.3M |
| Shareholders' Equity | $46.6M | $19.7M | $-6.0M |
| Retained Earnings | $-1.15B | $-1.20B | $-1.24B |
| AOCI | $-186.0K | $229.0K | $0 |
| Total L&E | $108.8M | $77.3M | $41.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-56.7M | $-47.4M | $-43.4M |
| Non-Cash Adjustments | $4.4M | $6.2M | $4.1M |
| Working Capital Changes | $-2.0M | $2.8M | $-278.0K |
| Cash from Operations | $-54.3M | $-38.4M | $-39.6M |
| Capital Expenditures | $416.0K | $0 | — |
| Cash from Investing | $33.0M | $37.8M | $29.4M |
| Cash from Financing | $867.0K | $7.6M | $3.4M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-20.4M | $6.9M | $-6.7M |
| Beginning Cash | $40.7M | $20.3M | $27.2M |
| Ending Cash | $20.3M | $27.2M | $20.5M |
Frequently Asked Questions
How does CURIS INC make money?
Oncology Therapeutics (primary revenue stream from product sales and licensing), Research Collaboration Partnerships (licensing fees and milestones), and Biologics Development (investing in novel antibody-drug conjugates).
What are the main risks for CRIS?
Substantial cash burn of $39.6M requiring continuous capital raises to fund operations, high probability of clinical trial failures typical in biotech, dilution from equity issuances, and potential regulatory hurdles for new drug approvals.
What is CRIS's competitive advantage?
Specialized expertise in developing antibody-drug conjugates for hard-to-treat cancer subtypes, a pipeline with multiple late-stage clinical assets, and strategic partnerships that mitigate development risk.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.